financetom
Business
financetom
/
Business
/
Entergy Insider Sold Shares Worth $875,000, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Entergy Insider Sold Shares Worth $875,000, According to a Recent SEC Filing
Sep 19, 2024 12:32 AM

04:25 PM EDT, 09/17/2024 (MT Newswires) -- Peter S Norgeot Jr, Executive Vice President & Chief Operating Officer, on September 13, 2024, sold 7,000 shares in Entergy ( ETR ) for $875,000. Following the Form 4 filing with the SEC, Norgeot has control over a total of 34,993 shares of the company, with 34,993 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/65984/000112760224024082/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Nov 13, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Medical device maker Biofrontera Q3 revenue falls more than expected on advanced purchases in 2024
Nov 13, 2025
Overview * Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024 * Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates * Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments Outlook * Company anticipates substantial 4Q25 and annual revenue growth due to price normalization * Biofrontera expects enhanced...
Ondas Q3 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Raised
Ondas Q3 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Raised
Nov 13, 2025
08:23 AM EST, 11/13/2025 (MT Newswires) -- Ondas ( ONDS ) reported a Q3 net loss Thursday of $0.03 per diluted share, narrowing from a loss of $0.15 a year earlier. Four analysts polled by FactSet expected a loss of $0.05. Net revenue for the quarter ended Sept. 30 was $10.1 million, compared with $1.5 million a year earlier. Analysts...
Copyright 2023-2026 - www.financetom.com All Rights Reserved